What infection control interventions should be undertaken to control multidrug-resistant gram-negative bacteria?

Clinical Infectious Diseases

Volumn 43, Issue SUPPL. 2, 2006, Pages

  Harris, Anthony D ^a,b   McGregor, Jessina C ^a   Furuno, Jon P ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAMASE; CARBAPENEM; METICILLIN; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BACTERIUM ISOLATION; COMORBIDITY; CONFERENCE PAPER; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INTERVENTION STUDY; KLEBSIELLA; MEDICAL PRACTICE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; CROSS INFECTION; ECONOMICS; HEALTH SURVEY; METHODOLOGY; PATIENT CARE; PRACTICE GUIDELINE; REVIEW; STANDARD;

CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFECTION CONTROL; PATIENT ISOLATION; PRACTICE GUIDELINES; SENTINEL SURVEILLANCE;

EID: 33747604662     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/504479     Document Type: Conference Paper

References (53)

1. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32:470-85.
2. Paterson DL, Rossi F, Baquero F, et al. In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 2005; 55:965-73.
3. Sader HS, Castanheira M, Mendes RE, Toleman M, Walsh TR, Jones RN. Dissemination and diversity of metallo-beta-lactamases in Latin America: report from the SENTRY Antimicrobial Surveillance Program. Int J Antimicrob Agents 2005; 25:57-61.
4. DiPersio JR, Deshpande LM, Biedenbach DJ, Toleman MA, Walsh TR, Jones RN. Evolution and dissemination of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae: epidemiology and molecular report from the SENTRY Antimicrobial Surveillance Program (1997-2003). Diagn Microbiol Infect Dis 2005; 51:1-7.
5. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant gram-negative bacteria. Int J Antimicrob Agents 2005; 25:11-25.
6. Coelho J, Woodford N, Turton J, Livermore DM. Multiresistant Acinetobacter in the UK: how big a threat? J Hosp Infect 2004; 58:167-9.
7. Wenzel RP. The antibiotic pipeline-challenges, costs, and values. N Engl J Med 2004; 351:523-6.
8. Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol 2003; 24:362-86.
9. Boyce JM, Havill NL, Kohan C, Dumigan DG, Ligi CE. Do infection control measures work for methicillin-resistant Staphylococcus aureus? Infect Control Hosp Epidemiol 2004; 25:395-401.
10. Ostrowsky B, Steinberg JT, Farr B, Sohn AH, Sinkowitz-Cochran RL, Jarvis WR. Reality check: should we try to detect and isolate vancomycin-resistant enterococci patients? Infect Control Hosp Epidemiol 2001; 22:116-9.
11. D'Agata EM, Gautam S, Green WK, Tang YW. High rate of false-negative results of the rectal swab culture method in detection of gastrointestinal colonization with vancomycin-resistant enterococci. Clin Infect Dis 2002; 34:167-72.
12. Ostrowsky BE, Venkataraman L, D'Agata EM, Gold HS, DeGirolami PC, Samore MH. Vancomycin-resistant enterococci in intensive care units: high frequency of stool carriage during a non-outbreak period. Arch Intern Med 1999; 159:1467-72.
13. Lam S, Singer C, Tucci V, Morthland VH, Pfaller MA, Isenberg HD. The challenge of vancomycin-resistant enterococci: a clinical and epidemiologic study. Am J Infect Control 1995; 23:170-80.
14. Montecalvo MA, de Lencastre H, Carraher M, et al. Natural history of colonization with vancomycin-resistant Enterococcus faecium. Infect Control Hosp Epidemiol 1995; 16:680-5.
15. Warren DK, Nitin A, Hill C, Fraser VJ, Kollef MH. Occurrence of co-colonization or co-infection with vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus in a medical intensive care unit. Infect Control Hosp Epidemiol 2004; 25:99-104.
16. Chang FY, Singh N, Gayowski T, Wagener MM, Marino IR. Staphylococcus aureus nasal colonization in patients with cirrhosis: prospective assessment of association with infection. Infect Control Hosp Epidemiol 1998; 19:328-32.
17. Garrouste-Orgeas M, Timsit IF, Kallel H, et al. Colonization with methicillin-resistant Staphylococcus aureus in ICU patients: morbidity, mortality, and glycopeptide use. Infect Control Hosp Epidemiol 2001; 22:687-92.
18. Coello R, Glynn JR, Gaspar C, Picazo JJ, Fereres I. Risk factors for developing clinical infection with methicillin-resistant Staphylococcus aureus (MRSA) amongst hospital patients initially only colonized with MRSA. I Hosp Infect 1997; 37:39-46.
19. Harris AD, Nemoy L, Johnson JA, et al. Co-carriage rates of vancomycin-resistant Enterococcus and extended-spectrum beta-lactamase-producing bacteria among a cohort of intensive care unit patients: implications for an active surveillance program. Infect Control Hosp Epidemiol 2004; 25:105-8.
20. Bertrand X, Thouverez M, Talon D, et al. Endemicity, molecular diversity, and colonisation routes of Pseudomonas aeruginosa in intensive care units. Intensive Care Med 2001; 27:1263-8.
21. Recommendations for preventing the spread of vancomycin resistance. Hospital Infection Control Practices Advisory Committee (HICPAC). Infect Control Hosp Epidemiol 1995; 16:105-13
22. [erratum: Infect Control Hosp Epidemiol 1995; 16:498].
23. Harbarth S, Liassine N, Dharan S, Herrault P, Auckenthaler R, Pittet D. Risk factors for persistent carriage of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2000; 31:1380-5.
24. Scanvic A, Denic L, Gaillon S, Giry P, Andremont A, Lucet JC. Duration of colonization by methicillin-resistant Staphylococcus aureus after hospital discharge and risk factors for prolonged carriage. Clin Infect Dis 2001; 32:1393-8.
25. Rahimi AR. Prevalence and outcome of methicillin-resistant Staphylococcus aureus colonization in two nursing centers in Georgia. J Am Geriatr Soc 1998; 46:1555-7.
26. Byers KE, Anglim AM, Anneski CJ, Farr BM. Duration of colonization with vancomycin-resistant Enterococcus. Infect Control Hosp Epidemiol 2002; 23:207-11.
27. Bird I, Browning R, Hobson RP, MacKenzie FM, Brand I, Gould IM. Multiply-resistant Klebsiella pneumoniae: failure of spread in community-based elderly care facilities. J Hosp Infect 1998; 40:243-7.
28. Pacio GA, Visintainer P, Maguire G, Wormser GP, Raffalli I, Montecalvo MA. Natural history of colonization with vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and resistant gram-negative bacilli among long-term-care facility residents. Infect Control Hosp Epidemiol 2003; 24:246-50.
29. Brennen C, Wagener MM, Müder RR. Vancomycin-resistant Enterococcus faecium in a long-term care facility. J Am Geriatr Soc 1998; 46:157-60.
30. Bonten MJ, Slaughter S, Ambergen AW, et al. The role of "colonization pressure" in the spread of vancomycin-resistant enterococci: an important infection control variable. Arch Intern Med 1998; 158:1127-32.
31. Merrer J, Santoli F, Appere de Vecchi C, Tran B, De Jonghe B, Outin H. "Colonization pressure" and risk of acquisition of methicillin-resistant Staphylococcus aureus in a medical intensive care unit. Infect Control Hosp Epidemiol 2000; 21:718-23.
32. Martinez JA, Ruthazer R, Hansjosten K, Barefoot L, Snydman DR. Role of environmental contamination as a risk factor for acquisition of vancomydn-resistant enterococci in patients treated in a medical intensive care unit. Arch Intern Med 2003; 163:1905-12.
33. Muder RR, Brennen C, Drenning SD, Stout JE, Wagener MM. Multiply antibiotic-resistant gram-negative bacilli in a long-term-care facility: a case-control study of patient risk factors and prior antibiotic use. Infect Control Hosp Epidemiol 1997; 18:809-13.
34. Ortega B, Groeneveld AB, Schultsz C. Endemic multidrug-resistant Pseudomonas aeruginosa in critically ill patients. Infect Control Hosp Epidemiol 2004; 25:825-31.
35. Olson B, Weinstein RA, Nathan C, Chamberlin W, Kabins SA. Occult aminoglycoside resistance in Pseudomonas aeruginosa: epidemiology and implications for therapy and control. J Infect Dis 1985; 152:769-74.
36. Weinstein RA, Nathan C, Gruensfelder R, Kabins SA. Endemic aminoglycoside resistance in gram-negative bacilli: epidemiology and mechanisms. J Infect Dis 1980; 141:338-45.
37. Olson B, Weinstein RA, Nathan C, Chamberlin W, Kabins SA. Epidemiology of endemic Pseudomonas aeruginosa: why infection control efforts have failed. J Infect Dis 1984; 150:808-16.
38. Bonten MJ, Bergmans DC, Speijer H, Stobberingh EE. Characteristics of polyclonal endemicity of Pseudomonas aeruginosa colonization in intensive care units: implications for infection control. Am J Respir Crit Care Med 1999; 160:1212-9.
39. Berthelot P, Grattard F, Mahul P, et al. Prospective study of nosocomial colonization and infection due to Pseudomonas aeruginosa in mechanically ventilated patients. Intensive Care Med 2001; 27:503-12.
40. Chetchotisakd P, Phelps CL, Hartstein AI. Assessment of bacterial cross-transmission as a cause of infections in patients in intensive care units. Clin Infect Dis 1994; 18:929-37.
41. Bergmans DC, Bonten MJ, van Tiel FH, et al. Cross-colonisation with Pseudomonas aeruginosa of patients in an intensive care unit. Thorax 1998; 53:1053-8.
42. Reuter S, Sigge A, Wiedeck H, Trautmann M. Analysis of transmission pathways of Pseudomonas aeruginosa between patients and tap water outlets. Crit Care Med 2002; 30:2222-8.
43. Bonten MJ, Weinstein RA. Transmission pathways of Pseudomonas aeruginosa in intensive care units: don't go near the water. Crit Care Med 2002; 30:2384-5.
44. Gardam MA, Burrows LL, Kus JV, et al. Is surveillance for multidrug-resistant enterobacteriaceae an effective infection control strategy in the absence of an outbreak? J Infect Dis 2002; 186:1754-60.
45. Lucet IC, Regnier B. Enterobacteria producing extended spectrum beta-lactamases [in French]. Pathol Biol (Paris) 1998; 46:235-43.
46. Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002-2004. MMWR Morb Mortal Wkly Rep 2004; 53:1063-6.
47. Jain R, Danziger LH. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann Pharmacother 2004; 38:1449-59.
48. Urban C, Segal-Maurer S, Rahal IJ. Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. Clin Infect Dis 2003; 36:1268-74.
49. Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin Infect Dis 2001; 32(Suppl 2):S104-13.
50. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 2005; 41:848-54.
51. Manikal VM, Landman D, Saurina G, Oydna E, LaI H, Quale J. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis 2000; 31:101-6.
52. Turton JF, Kaufmann ME, Warner M, et al. A prevalent, multiresistant done of Acinetobacter baumannii in southeast England. J Hosp Infect 2004; 58:170-9.
53. Perencevich EN, Fisman DN, Lipsitch M, Harris AD, Morris JG Jr, Smith DL. Projected benefits of active surveillance for vancomycin-resistant enterococci in intensive care units. Clin Infect Dis 2004; 38:1108-15.